

03-04-04

Docket No: AM100635
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Lee D. Jennings
Application No.: 10/731,723 Group Art No.:
Filed: December 9, 2003 Examiner:
For: Substituted 3-Carbonyl-1H-Indol-1-yl-Acetic Acid Derivatives as
Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)
Confirmation No.:
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947814271US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

3-3-04
Date


John R. Barker

Identification of Time of Filing

This Information Disclosure Statement

- a. ☒ is filed within three months of the filing date of the application.
b. ☐ is filed before the mailing date of a first Office Action on the merits.
c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

☐ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Application Number _____, filed on _____ of _____ for _____



- ☒ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
b. ☒ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:
Charge Deposit Account No. 01-1425 in the amount of
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No.
01-1425.

Michael R. Nagy
March 3, 2004
Attorney for Applicants
Reg. No. 33,432

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8616

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		10/731,723
				Filing Date		December 9, 2003
				First Named Inventor		Lee D. Jennings
				Group Art Unit		
Examiner Name						
Attorney Docket Number		AM100635				
Sheet	1	of	1			

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,612,360		Donald B. Boyd et al.	03-18-1997	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	97/48697		Paul J. Cox et al.	12-24-1997		<input type="checkbox"/>
	3.	WO	99/43651		Jasbir S. Seehra et al.	09-02-1999		<input type="checkbox"/>
	4.	WO	99/43654		Jasbir S. Seehra et al.	09-02-1999		<input type="checkbox"/>
	5.	EP	1 156 045		Norihisa Taniguchi et al.	11-21-2001		<input type="checkbox"/>
	6.	GB	1 321 433		Roussel-Uclaf	06-27-1973		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.		T
	7.	Chitra KRISHNAMURTI et al., Blood, March 1987, 798-803, 69(3)	<input type="checkbox"/>
	8.	Christopher F. REILLY et al., Arteriosclerosis and Thrombosis, Sept./Oct. 1991, 1276-1286, 11(5)	<input type="checkbox"/>
	9.	Peter CARMELIET et al., J. Clin. Investigations, 1993, 2756-2760, 92	<input type="checkbox"/>
	10.	E. ROCHA et al., Fibrinolysis, 1994, 294-303, 8	<input type="checkbox"/>
	11.	Justo AZNAR et al., Haemostasis, 1994, 243-251, 24	<input type="checkbox"/>
	12.	B.J. BIEMOND et al., Circulation, 1995, 1175-1181, 91(4)	<input type="checkbox"/>
	13.	Marcel LEVI et al., Circulation, January 1992, 305-312, 85(1)	<input type="checkbox"/>
	14.	Thomas K. NORDT et al., J. Clin. Endocrinology and Metabolism, 2000, 1563-1568, 85(4)	<input type="checkbox"/>
	15.	E. DACI et al., J. Bone and Mineral Research, 2000, 1510-1516, 15(8)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.